OPTISON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTISON (OPTISON).
OPTISON consists of perflutren protein-type A microspheres that act as an ultrasound contrast agent by increasing the echogenicity of blood, improving the visualization of cardiac chambers and intracardiac blood flow.
| Metabolism | Perflutren microspheres are eliminated via the lungs; the albumin shell is metabolized by the reticuloendothelial system. |
| Excretion | Primarily eliminated via pulmonary excretion of the perfluoropropane gas; <1% renal excretion of the intact microsphere components. |
| Half-life | Plasma half-life of perfluoropropane gas is approximately 2.4 minutes after intravenous administration, with rapid equilibration and elimination via the lungs. |
| Protein binding | Minimal to negligible protein binding; the microsphere shell components (human albumin) are present in negligible amounts. |
| Volume of Distribution | Approximately 0.3 L/kg, indicating distribution primarily within the vascular compartment and minimal tissue penetration. |
| Bioavailability | Intravenous: 100% (administered as an IV bolus); not administered by other routes. |
| Onset of Action | Intravenous: immediately upon injection (within seconds) as contrast enhancement is seen during the first pass. |
| Duration of Action | Intravenous: contrast enhancement typically lasts 4-5 minutes, allowing for adequate imaging windows; may persist up to 10 minutes in some patients. |
0.5 mL intravenous bolus; may repeat with additional 0.5 mL dose if needed. Administer via peripheral intravenous line at 1 mL/sec.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not established for use in pediatric patients (safety and efficacy in children have not been studied). |
| Geriatric use | No specific dose adjustment recommended; use with consideration of age-related physiological changes that may affect cardiac function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTISON (OPTISON).
| Breastfeeding | No data on excretion in human milk. Caution advised due to potential for infant exposure. M/P ratio is not available. |
| Teratogenic Risk | Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: Avoid unless benefit outweighs risk. Second and third trimesters: Limited data, but no known teratogenic effects. |
| Fetal Monitoring |
■ FDA Black Box Warning
Warning: Serious cardiopulmonary reactions, including fatalities, have occurred during or within 30 minutes following administration of OPTISON. These reactions include cardiac arrest, cardiopulmonary arrest, respiratory arrest, shock, and hypotension. Resuscitative equipment and trained personnel must be immediately available.
| Serious Effects |
["Known or suspected right-to-left, bidirectional, or transient right-to-left cardiac shunts","Hypersensitivity to perflutren, albumin, or any component of the product"]
| Precautions | ["High risk of serious cardiopulmonary reactions including fatal cardiac arrest","Caution in patients with unstable cardiopulmonary conditions (e.g., acute myocardial infarction, acute coronary syndrome, worsening or unstable heart failure)","Anaphylactic and allergic reactions possible","QT prolongation observed; avoid in patients with known QT prolongation or risk factors","Extravasation may cause local tissue injury"] |
Loading safety data…
| Monitor maternal vital signs (blood pressure, heart rate) and oxygen saturation during and after administration. Fetal heart rate monitoring is recommended if clinically feasible. |
| Fertility Effects | No known effects on fertility in animals or humans. |